MCID: TRM010
MIFTS: 53

Traumatic Brain Injury

Categories: Ear diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Traumatic Brain Injury

MalaCards integrated aliases for Traumatic Brain Injury:

Name: Traumatic Brain Injury 53 42 3 37

Classifications:



Summaries for Traumatic Brain Injury

MedlinePlus : 42 Traumatic brain injury (TBI) happens when a bump, blow, jolt, or other head injury causes damage to the brain. Every year, millions of people in the U.S. suffer brain injuries. More than half are bad enough that people must go to the hospital. The worst injuries can lead to permanent brain damage or death. Half of all TBIs are from motor vehicle accidents. Military personnel in combat zones are also at risk. Symptoms of a TBI may not appear until days or weeks following the injury. A concussion is the mildest type. It can cause a headache or neck pain, nausea, ringing in the ears, dizziness, and tiredness. People with a moderate or severe TBI may have those, plus other symptoms: A headache that gets worse or does not go away Repeated vomiting or nausea Convulsions or seizures Inability to awaken from sleep Slurred speech Weakness or numbness in the arms and legs Dilated eye pupils Health care professionals use a neurological exam and imaging tests to assess TBI. Serious traumatic brain injuries need emergency treatment. Treatment and outcome depend on how severe the injury is. TBI can cause a wide range of changes affecting thinking, sensation, language, or emotions. TBI can be associated with post-traumatic stress disorder. People with severe injuries usually need rehabilitation. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Traumatic Brain Injury is related to head injury and persistent vegetative state. An important gene associated with Traumatic Brain Injury is APOE (Apolipoprotein E), and among its related pathways/superpathways are Neuroscience and JAK-STAT signaling pathway (KEGG). The drugs Diclofenac and Cisatracurium have been mentioned in the context of this disorder. Affiliated tissues include Bone, brain and testes, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

CDC : 3 Traumatic brain injury (TBI) is a serious public health problem in the United States. Each year, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability. In 2014, there were approximately 2.87 million TBI-related emergency department visits, hospitalizations, and deaths in the US, including over 837,000 of these health events among children. 1 A TBI is caused by a bump, blow or jolt to the head or a penetrating head injury that disrupts the normal function of the brain. Not all blows or jolts to the head result in a TBI. The severity of a TBI may range from "mild," i.e., a brief change in mental status or consciousness to "severe," i.e., an extended period of unconsciousness or amnesia after the injury. CDC's research and programs work to prevent TBI and help people better recognize, respond, and recover if a TBI occurs.

NINDS : 53 Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.  Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.  A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

Wikipedia : 74 Traumatic brain injury (TBI), also known as intracranial injury, occurs when an external force injures... more...

Related Diseases for Traumatic Brain Injury

Diseases related to Traumatic Brain Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 785)
# Related Disease Score Top Affiliating Genes
1 head injury 33.7 S100B ENO2 APOE
2 persistent vegetative state 33.3 ENO2 APOE
3 normal pressure hydrocephalus 32.3 IGF1 GFAP BDNF AQP4 APOE
4 amnestic disorder 31.7 S100B DRD2 BDNF APOE
5 obsessive-compulsive disorder 31.6 IL6 IGF1 DRD2 COMT BDNF APOE
6 dementia 31.6 UCHL1 GFAP DRD2 COMT BDNF APOE
7 brain edema 31.5 MMP9 IL6 GFAP AQP4
8 cerebral hypoxia 31.4 IGF1 CASP3
9 post-traumatic stress disorder 31.3 DRD2 COMT BDNF APOE
10 substance abuse 31.2 DRD2 COMT BDNF
11 status epilepticus 30.9 GFAP ENO2 CASP3 BDNF
12 sleep disorder 30.9 IL6 IGF1 DRD2 BDNF
13 mental depression 30.8 IL6 DRD2 COMT BDNF
14 cerebral artery occlusion 30.8 BDNF AQP4 APOE
15 hemiplegia 30.8 S100B MMP9 ENO2
16 pituitary gland disease 30.8 IGF1 GH1 DRD2
17 generalized anxiety disorder 30.8 DRD2 COMT BDNF
18 personality disorder 30.8 DRD2 COMT BDNF
19 alcohol use disorder 30.8 DRD2 COMT BDNF
20 anxiety 30.7 IL6 DRD2 COMT BDNF APOE
21 alexithymia 30.7 IL6 DRD2 COMT
22 akinetic mutism 30.6 S100B MBP ENO2
23 migraine with or without aura 1 30.6 IL6 DRD2 COMT BDNF
24 obstructive hydrocephalus 30.5 GFAP ENO2 AQP4
25 psychotic disorder 30.5 S100B DRD2 COMT BDNF
26 spinal cord injury 30.5 MMP9 IL6 GFAP CASP3 BDNF AQP4
27 chiari malformation 30.4 MBP GFAP
28 decubitus ulcer 30.4 MMP9 IL6 IGF1
29 arteriovenous malformation 30.4 MMP9 IL6 APOE
30 ganglioglioma 30.3 S100B GFAP ENO2
31 non-functioning pituitary adenoma 30.3 S100B GH1
32 asphyxia neonatorum 30.2 S100B ENO2 CASP3
33 disease of mental health 30.2 IL6 DRD2 COMT BDNF APOE
34 peripheral artery disease 30.2 IL6 IGF1 APOE
35 endogenous depression 30.2 IL6 COMT BDNF
36 central precocious puberty 30.1 IGF1 GH1
37 borderline personality disorder 30.1 DRD2 COMT BDNF
38 alexander disease 30.1 GFAP CASP3 AQP4
39 prion disease 30.1 GFAP ENO2 APOE
40 apnea, obstructive sleep 30.1 IL6 IGF1 APOE
41 mood disorder 30.0 MMP9 IL6 GFAP DRD2 COMT BDNF
42 optic nerve disease 30.0 MBP IL6 GFAP BDNF AQP4
43 hyperprolactinemia 30.0 IGF1 GH1 DRD2
44 encephalomalacia 30.0 S100B MBP IL6 GFAP CASP3 BDNF
45 meningioma, familial 30.0 MMP9 IGF1 GFAP ENO2
46 intracranial hypertension, idiopathic 30.0 IGF1 GH1 AQP4
47 neuroaxonal dystrophy 29.9 MBP IGF1 ENO2
48 polysubstance abuse 29.9 DRD2 COMT
49 retinal vascular disease 29.9 IL6 IGF1 CASP3
50 multiple system atrophy 1 29.9 MBP GFAP DRD2

Graphical network of the top 20 diseases related to Traumatic Brain Injury:



Diseases related to Traumatic Brain Injury

Symptoms & Phenotypes for Traumatic Brain Injury

GenomeRNAi Phenotypes related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 IGF1 IL10
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Traumatic Brain Injury:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 APOE AQP4 BDNF CASP3 COMT DRD2
2 growth/size/body region MP:0005378 10.39 APOE AQP4 BDNF CASP3 DRD2 ENO2
3 cardiovascular system MP:0005385 10.36 APOE AQP4 CASP3 COMT DRD2 GFAP
4 homeostasis/metabolism MP:0005376 10.36 APOE AQP4 BDNF CASP3 COMT DRD2
5 cellular MP:0005384 10.35 APOE BDNF CASP3 DRD2 ENO2 GFAP
6 nervous system MP:0003631 10.28 APOE AQP4 BDNF CASP3 COMT DRD2
7 digestive/alimentary MP:0005381 10.27 APOE AQP4 BDNF CASP3 DRD2 GFAP
8 mortality/aging MP:0010768 10.27 APOE AQP4 BDNF CASP3 DRD2 GFAP
9 hematopoietic system MP:0005397 10.26 APOE AQP4 CASP3 COMT DRD2 IGF1
10 immune system MP:0005387 10.24 APOE AQP4 CASP3 COMT DRD2 GFAP
11 endocrine/exocrine gland MP:0005379 10.21 APOE AQP4 BDNF CASP3 COMT DRD2
12 integument MP:0010771 10.18 APOE BDNF CASP3 DRD2 IGF1 IL10
13 muscle MP:0005369 10.03 APOE CASP3 DRD2 GFAP IGF1 IL10
14 hearing/vestibular/ear MP:0005377 10.01 APOE AQP4 BDNF CASP3 IGF1 MBP
15 normal MP:0002873 9.97 BDNF DRD2 GFAP IGF1 IL10 MBP
16 renal/urinary system MP:0005367 9.97 APOE AQP4 CASP3 COMT DRD2 IGF1
17 reproductive system MP:0005389 9.96 APOE BDNF CASP3 COMT DRD2 IGF1
18 respiratory system MP:0005388 9.93 APOE AQP4 BDNF CASP3 COMT DRD2
19 taste/olfaction MP:0005394 9.35 APOE BDNF CASP3 DRD2 ENO2
20 vision/eye MP:0005391 9.28 APOE AQP4 BDNF CASP3 GFAP IL10

Drugs & Therapeutics for Traumatic Brain Injury

Drugs for Traumatic Brain Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 442)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Cisatracurium Approved Phase 4 96946-41-7
3
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Quinidine Approved, Investigational Phase 4 56-54-2 441074
6
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
7
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
8
Ethanol Approved Phase 4 64-17-5 702
9
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Fosphenytoin Approved, Investigational Phase 4 93390-81-9 56339
12
Simvastatin Approved Phase 4 79902-63-9 54454
13
Sertraline Approved Phase 4 79617-96-2 68617
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
16
Phenylephrine Approved Phase 4 59-42-7 6041
17
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Haloperidol Approved Phase 4 52-86-8 3559
20
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
21
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Pseudoephedrine Approved Phase 4 90-82-4 7028
24
Ephedrine Approved Phase 4 299-42-3 9294
25
Amantadine Approved Phase 4 768-94-5 2130
26
Prazosin Approved Phase 4 19216-56-9 4893
27
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
28
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
29
Propranolol Approved, Investigational Phase 4 525-66-6 4946
30
Topiramate Approved Phase 4 97240-79-4 5284627
31
Levetiracetam Approved Phase 4 102767-28-2 441341
32
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
36
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
37 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
38
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
39
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
40
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
41
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
42
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
43
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
44
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
45
Donepezil Approved Phase 4 120014-06-4 3152
46
Amitriptyline Approved Phase 4 50-48-6 2160
47
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
48
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
49
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
50
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3

Interventional clinical trials:

(show top 50) (show all 1392)
# Name Status NCT ID Phase Drugs
1 Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI) Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
2 A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
3 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
4 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
5 Normothermia in Patients With Acute Cerebral Damage Unknown status NCT00491192 Phase 4 Diclofenac
6 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
7 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo Unknown status NCT02404779 Phase 4 cisatracurium besilate
8 Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients Unknown status NCT00505505 Phase 4 Insulin (Actrapid)
9 Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
10 Citicholine-Amantadine Trial in Traumatic Brain Injury Unknown status NCT03430817 Phase 4 Citicholine;Amantadine
11 A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment Unknown status NCT00163878 Phase 4
12 Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial Unknown status NCT01833624 Phase 4
13 Administration of Tranexamic Acid in the Preclinical Setting and Its Effect on Coagulation Parameters and Outcome in Multiple Trauma Patients and Isolated TBI in EMS (Schutz Und Rettung Zürich) and Helicopter Rescue(REGA). Unknown status NCT02354885 Phase 4 Tranexamic Acid
14 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
15 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
16 A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits Completed NCT00219245 Phase 4 Rivastigmine
17 Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System) Completed NCT00205491 Phase 4 Venlafaxine
18 Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs Completed NCT02130674 Phase 4 Dipeptiven
19 Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits Completed NCT02712996 Phase 4 Lisdexamfetamine;Placebo
20 Beta-Adrenergic Blockade for Suppression of Catecholamine Surge Following Traumatic Brain Injury: A Randomized Trial Completed NCT02957331 Phase 4 Propranolol
21 Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI Completed NCT01750268 Phase 4 Topiramate;Placebo
22 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
23 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
24 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
25 Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI Completed NCT01952288 Phase 4 simvastatin;Placebo Oral Tablet
26 Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit Completed NCT00618436 Phase 4 Levetiracetam;Phenytoin
27 Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
28 Amantadine Hydrochloride for Treatment of Symptoms of the Post-traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT00693121 Phase 4 Amantadine hydrochloride;Placebo capsule
29 The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury Completed NCT00254007 Phase 4 citalopram (celexa)
30 The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition Completed NCT02015949 Phase 4 Methylphenidate;Placebo
31 Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery Completed NCT00035139 Phase 4 methylphenidate
32 Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients Completed NCT03480880 Phase 4
33 Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure Completed NCT00447018 Phase 4 20% mannitol;7.45% hypertonic saline solution
34 Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study Completed NCT01809639 Phase 4 Progesterone;Placebo
35 A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
36 Abobotulinumtoxina Efficacy in Post-Traumatic Headache Completed NCT03928496 Phase 4 AbobotulinumtoxinA;Normal saline
37 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
38 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine
39 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
40 Progesterone Augmentation of Nicotine Replacement Therapy Study Completed NCT02685072 Phase 4 Progesterone (200 mgs BID);Placebo
41 Restrictive vs. Liberal Oxygen Therapy for Trauma Patients. PILOT: The TRAUMOX Trial Completed NCT03491644 Phase 4 Titrated Oxygen;Liberal Oxygen
42 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study Completed NCT02496650 Phase 4 Dexmedetomidine
43 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
44 Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate Completed NCT01692769 Phase 4 Normal Saline;Ringer's Lactate
45 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
46 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
47 A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients. Completed NCT00220987 Phase 4
48 EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES Completed NCT01651988 Phase 4 Ketamina-Propofol Combination
49 Cerebral Protection of Dexmedetomidine Against Paroxysmal Sympathetic Overexcited in Patients With Traumatic Brain Injury Recruiting NCT04006054 Phase 4 Dexmedetomidine;Midazolam
50 Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury Recruiting NCT02321761 Phase 4 Amantadine hydrochloride

Search NIH Clinical Center for Traumatic Brain Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Traumatic Brain Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Traumatic Brain Injury:
MultiStem, bone marrow-derived cells for neurological disorders
Embryonic/Adult Cultured Cells Related to Traumatic Brain Injury:
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119

Genetic Tests for Traumatic Brain Injury

Anatomical Context for Traumatic Brain Injury

MalaCards organs/tissues related to Traumatic Brain Injury:

40
Brain, Testes, Bone, Spinal Cord, Cortex, Pituitary, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Traumatic Brain Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Traumatic Brain Injury

Articles related to Traumatic Brain Injury:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
Comparison of admission serum albumin and hemoglobin as predictors of outcome in children with moderate to severe traumatic brain injury: A retrospective study. 61 42
31689863 2019
2
Biochemical Mechanisms and Translational Relevance of Hippocampal Vulnerability to Distant Focal Brain Injury: The Price of Stress Response. 42
31760920 2019
3
Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Brain Injury. 42
31777018 2019
4
Fast-tracking regenerative medicine for traumatic brain injury. 61
31960797 2020
5
Adrenomedullin: an important participant in neurological diseases. 61
31960799 2020
6
Moderate/severe traumatic brain injury as a trigger of chronic neurodegeneration in humans. 61
31960805 2020
7
Risk factors for corticosteroid insufficiency during the sub-acute phase of acute traumatic brain injury. 61
31960811 2020
8
The extended renin-angiotensin system: a promising target for traumatic brain injury therapeutics. 61
31823875 2020
9
Remote ischemic conditioning improves outcome independent of anesthetic effects following shockwave-induced traumatic brain injury. 61
31909289 2020
10
Surfing-related head injuries presenting to United States emergency departments. 61
32025130 2020
11
Inhibiting endogenous tissue plasminogen activator enhanced neuronal apoptosis and axonal injury after traumatic brain injury. 61
31638090 2020
12
Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head trauma. 61
31638091 2020
13
Caffeine consumption during development alters spine density and recovery from repetitive mild traumatic brain injury in young adult rats. 61
31705690 2020
14
Connecting endoplasmic reticulum and oxidative stress to retinal degeneration, TBI, and traumatic optic neuropathy. 61
31642095 2020
15
Juvenile mild traumatic brain injury elicits distinct spatiotemporal astrocyte responses. 61
31670865 2020
16
Roles of glial ion transporters in brain diseases. 61
31418931 2020
17
Modulation of autophagy in traumatic brain injury. 61
31512236 2020
18
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma. 61
31238788 2020
19
Role of quetiapine in protection of neurodegeneration after traumatic brain injury. 61
30913942 2020
20
Posttraumatic Stress Disorder, Traumatic Brain Injury, Sleep, and Performance in Military Personnel. 61
32005353 2020
21
Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. 61
32035565 2020
22
Management of Paroxysmal Sympathetic Hyperactivity with Dexmedetomidine and Propranolol Following Traumatic Brain Injury in a Pediatric Patient. 61
31984161 2020
23
Effect of eye movement reactivation on visual memory among individuals with moderate-to-severe traumatic brain injury (TBI). 61
31847796 2020
24
Validation of reference genes for gene expression analysis following experimental traumatic brain injury in a pediatric mouse model. 61
31904409 2020
25
A novel mouse model for the study of endogenous neural stem and progenitor cells after traumatic brain injury. 61
31751572 2020
26
Greater neurodegeneration and behavioral deficits after single closed head traumatic brain injury in adolescent versus adult male mice. 61
31541497 2020
27
Intranasal wnt-3a alleviates neuronal apoptosis in early brain injury post subarachnoid hemorrhage via the regulation of wnt target PPAN mediated by the moonlighting role of aldolase C. 61
31899197 2020
28
JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke. 61
31541462 2020
29
Management Strategies for Intracranial Pressure Crises in Subarachnoid Hemorrhage. 61
30514150 2020
30
Development and evaluation of an 1-day Acceptance and Commitment Therapy workshop for Veterans with comorbid chronic pain, TBI, and psychological distress: Outcomes from a pilot study. 61
32032736 2020
31
Photobiomodulation therapy for repeated closed head injury in rats. 61
31657525 2020
32
Pediatric minor head injury imaging practices: results from an ESPR survey. 61
31828360 2020
33
Urinary dysfunction in acute brain injury: A narrative review. 61
31786429 2020
34
TLR4 signaling in neurons enhances calcium-permeable AMPAR currents and drives post-traumatic epileptogenesis. 61
32031699 2020
35
Establishing a Regional Trauma Preventable/Potentially Preventable Death Rate. 61
30067544 2020
36
Microglia Adopt Longitudinal Transcriptional Changes After Traumatic Brain Injury. 61
31563831 2020
37
Oxygenation extremes after traumatic brain injury transiently affect coagulation. 61
31887624 2020
38
Tachycardia in a patient with mild traumatic brain injury. 61
31637539 2020
39
Multi-Directional Dynamic Model For Traumatic Brain Injury Detection. 61
31856650 2020
40
Spatial relational memory in individuals with traumatic brain injury. 61
31475607 2020
41
Age, symptoms, and functional outcome after mild traumatic brain injury. 61
31693184 2020
42
The need to incorporate aged animals into the preclinical modeling of neurological conditions. 61
31877345 2020
43
Anti-decubitus bed mattress may interfere with cerebrovascular pressure reactivity measures due to induced ICP and ABP cyclic peaks. 61
32036500 2020
44
Multi-Excitation MR Elastography of the Brain: Wave Propagation in Anisotropic White Matter. 61
32006012 2020
45
Are there any differential responses to concussive injury in civilian versus athletic populations: a neuroimaging study. 61
30361946 2020
46
Low-dose Quetiapine-induced Syndrome of Inappropriate Antidiuretic Hormone in a Patient with Traumatic Brain Syndrome. 61
31958918 2020
47
Long-Term Effect of Decompressive Craniectomy on Intracranial Pressure and Possible Implications for Intracranial Fluid Movements. 61
30768137 2020
48
Progressive Histopathological Damage Occurring Up to One Year after Experimental Traumatic Brain Injury Is Associated with Cognitive Decline and Depression-Like Behavior. 61
31847690 2020
49
Autonomic Hyperactivity. 61
31996626 2020
50
Traumatic brain injury and risk of dementia at different levels of cognitive ability and education. 61
31571318 2020

Variations for Traumatic Brain Injury

Expression for Traumatic Brain Injury

Search GEO for disease gene expression data for Traumatic Brain Injury.

Pathways for Traumatic Brain Injury

Pathways related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1 12.23 UCHL1 S100B MBP GFAP ENO2 COMT
2
Show member pathways
12.14 IL6 IL10 GH1 GFAP
3
Show member pathways
12.04 IL6 IL10 IGF1 GH1 BDNF
4 11.93 IL6 IL10 CASP3 BDNF AQP4
5 11.75 IL6 IL10 CASP3
6 11.6 IL6 IL10 CASP3
7 11.57 S100B IGF1 GFAP BDNF
8 11.53 MMP9 IL6 CASP3
9 11.51 MMP9 IGF1 GH1
10 11.49 MMP9 IL6 IGF1
11 11.38 UCHL1 IL6 CASP3
12 11.29 IL6 IGF1 APOE
13 11.25 MMP9 MBP IL6 GFAP CASP3 BDNF
14 11.21 IL10 IGF1 DRD2 BDNF
15 11.2 MMP9 IL6 IL10 IGF1 BDNF
16 10.78 IL6 IL10 IGF1 GH1 GFAP BDNF
17 10.7 CASP3 BDNF

GO Terms for Traumatic Brain Injury

Cellular components related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 S100B MMP9 IL6 IL10 IGF1 GH1
2 extracellular region GO:0005576 9.65 SPTAN1 S100B MMP9 IL6 IL10 IGF1
3 astrocyte end-foot GO:0097450 9.26 GFAP AQP4
4 neuronal cell body GO:0043025 9.1 UCHL1 S100B MBP ENO2 CASP3 APOE

Biological processes related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 IL10 DRD2 COMT CASP3
2 cytokine-mediated signaling pathway GO:0019221 9.85 MMP9 IL6 IL10 CASP3
3 negative regulation of apoptotic process GO:0043066 9.85 MMP9 IL6 IL10 IGF1 CASP3
4 axonogenesis GO:0007409 9.69 UCHL1 S100B DRD2
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL6 IGF1 GH1
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 IL6 IGF1 GH1
7 negative regulation of amyloid-beta formation GO:1902430 9.54 IGF1 APOE
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.52 IGF1 GH1
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.5 MMP9 IL10 IGF1
10 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.48 MBP IL10
11 regulation of neuroinflammatory response GO:0150077 9.43 MMP9 IL6
12 positive regulation of receptor binding GO:1900122 9.37 MMP9 BDNF
13 regulation of neurotransmitter uptake GO:0051580 9.26 GFAP DRD2
14 response to inactivity GO:0014854 9.16 IL10 DRD2
15 positive regulation of JAK-STAT cascade GO:0046427 9.13 IL6 IL10 GH1
16 response to glucocorticoid GO:0051384 8.92 S100B IL6 IL10 CASP3

Molecular functions related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 UCHL1 SPTAN1 S100B MMP9 MBP IL6
2 growth factor activity GO:0008083 9.02 IL6 IL10 IGF1 GH1 BDNF

Sources for Traumatic Brain Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....